Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?

Arthritis Care and Research

Volumn 67, Issue 6, 2015, Pages 746-753

  Marks, Jonathan L ^a   Holroyd, Christopher R ^a   Dimitrov, Borislav D ^b   Armstrong, Ray D ^a   Calogeras, Antonia ^a   Cooper, Cyrus ^b   Davidson, Brian K ^a   Dennison, Elaine M ^a   Harvey, Nicholas C ^b   Edwards, Christopher J ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOPPLER ECHOGRAPHY; DRUG DOSE REDUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT SELECTION; REMISSION; RHEUMATOID ARTHRITIS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DISABILITY; DOPPLER FLOWMETRY; DRUG EFFECTS; ECHOGRAPHY; IMMUNOLOGY; JOINT; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISABILITY EVALUATION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; ULTRASONOGRAPHY, DOPPLER;

EID: 84929866822     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22552     Document Type: Article

References (39)

1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al., A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000; 343: 1586-93.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al., Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
3. Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B, et al., Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009; 48: 1429-34.
4. Kimel M, Cifaldi M, Chen N, Revicki D., Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008; 35: 206-15.
5. Van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al., Disease activity, physical function, and radiographic progression after long-term therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010; 37: 2237-46.
6. Van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH., Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res (Hoboken) 2010; 62: 226-34.
7. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, et al., Clinical, functional, and radiographic benefits of long-term adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013; 40: 1487-97.
8. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
9. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
10. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al, and the British Society for Rheumatology Biologics Register. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810-4.
11. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al, and the British Society for Rheumatology Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
12. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al., BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010; 49: 2217-9.
13. National Institute for Health and Care Excellence. Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Technology Appraisal TA130. 2007. URL: https://www.nice.org.uk/guidance/ta130.
14. Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, et al., Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther 2013; 15: R135.
15. Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C., Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics 2012; 6: 201-6.
16. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al., Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013; 381: 918-29.
17. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al., Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35.
18. Rudolf MD, Deighton C, Bosworth A, Hall J, Hammond A, Hennel S, et al., Rheumatoid arthritis: national clinical guideline for management and treatment in adults. NICE Clinical Guidelines. London: Royal College of Physicians; 2009. URL: http://www.nice.org.uk/nicemedia/pdf/CG79FullGuideline.pdf.
19. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Wakefield R, et al., Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis 2011; 70: 792-8.
20. Ozgocmen S, Ozdemir H, Kiris A, Bozgeyik Z, Ardicoglu O., Clinical evaluation and power Doppler sonography in rheumatoid arthritis: evidence for ongoing synovial inflammation in clinical remission. South Med J 2008; 101: 240-5.
21. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al., Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-73.
22. Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D'Agostino MA, Backhaus M, et al., The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2013; 72: 665-71.
23. Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G., Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis 2011; 70: 172-5.
24. Colebatch AN, Edwards CJ, Ostergaard M, van der Heijde D, Balint PV, D'Agostino MA, et al., EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013; 72: 804-14.
25. Stone M, Bergin D, Whelan B, Maher M, Murray J, McCarthy C., Power Doppler ultrasound assessment of rheumatoid hand synovitis. J Rheumatol 2001; 28: 1979-82.
26. Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, Ostergaard M., Contrast-enhanced power Doppler ultrasonography of the metacarpophalangeal joints in rheumatoid arthritis. European Radiol 2003; 13: 163-8.
27. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al., 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
28. Fransen J, van Riel PL., The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 Suppl 39: S93-9.
29. Dale J, Purves D, McConnachie A, Porter D, McInnes IB., Tightening up: musculoskeletal ultrasound could further individualize treatment decisions in early rheumatoid arthritis patients treated by a step-up DMARD escalation regimen [abstract]. Arthritis Rheum 2012; 64 Suppl 10: S1129.
30. Dale J, Purves D, McConnachie A, McInnes I, Porter D., Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (Hoboken) 2014; 66: 19-26.
31. Keen HI, Wakefield RJ, Grainger AJ, Hensor EM, Emery P, Conaghan PG., Can ultrasonography improve on radiographic assessment in osteoarthritis of the hands? A comparison between radiographic and ultrasonographic detected pathology. Ann Rheum Dis 2008; 67: 1116-20.
32. Terslev L, Torp-Pedersen S, Qvistgaard E, von der Recke P, Bliddal H., Doppler ultrasound findings in healthy wrists and finger joints. Ann Rheum Dis 2004; 63: 644-8.
33. Witt M, Mueller F, Nigg A, Reindl C, Leipe J, Proft F, et al., Relevance of grade 1 gray-scale ultrasound findings in wrists and small joints to the assessment of subclinical synovitis in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1694-1701.
34. Emery PH, Hammoudeh M, Fitzgerald O, Combe B, Martin-Mola E, Bukowski J, et al., Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study [abstract]. Ann Rheum Dis 2013; 72 Suppl 3: 339.
35. Van Vollenhoven RV, Franck-Larsson K, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, et al., In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50 mg or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-arm, double-blind study [abstract]. Ann Rheum Dis 2013; 72: 434.
36. Ellegaard K, Torp-Pedersen S, Henriksen M, Lund H, Danneskiold-Samsoe B, Bliddal H., Influence of recent exercise and skin temperature on ultrasound Doppler measurements in patients with rheumatoid arthritis: an intervention study. Rheumatology (Oxford) 2009; 48: 1520-3.
37. Naredo E, Rodriguez M, Campos C, Rodriguez-Heredia JM, Medina JA, Giner E, et al., Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008; 59: 515-22.
38. Backhaus M, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, Hartung W, et al., Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum 2009; 61: 1194-1201.
39. Naredo E, Valor L, de la Torre I, Martinez-Barrio J, Hinojosa M, Aramburu F, et al., Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed? Arthritis Care Res (Hoboken) 2013; 65: 512-7.